Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, confirmed that the European Patent Office will grant a European Patent for its Moditope immunotherapy platform with effect from 13 June 2018.
The patent will provide broad protection for the company’s pipeline of Moditope vaccines, including any citrullinated epitopes for the treatment of cancer, in all major European territories including: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, UK, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.
Counterparts to this patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.
Moditope represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4 T cells, which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Moditope alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented: “This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins.”
“We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma.”
